首页> 外文期刊>Cancer Medicine >Epidemiology and practice patterns for male breast cancer compared with female breast cancer in Japan
【24h】

Epidemiology and practice patterns for male breast cancer compared with female breast cancer in Japan

机译:与日本女性乳腺癌相比雄性乳腺癌的流行病学和实践模式

获取原文
           

摘要

Background The incidence of male breast cancer (MBC), although rare, has shown an increase. However, the current epidemiology of and practice patterns for MBC remain unclear. This study evaluated the characteristics and care patterns for MBC compared with female breast cancer (FBC) in Japan. Methods Using the National Database of Hospital‐Based Cancer Registries (HBCR) linked to the Diagnosis Procedure Combination data, we analyzed newly diagnosed breast cancer cases between January 2012 and December 2015 at participating hospitals in a large quality‐of‐care monitoring project. We employed logistic regression models to assess cancer treatment differences between MBC and FBC in patients who were indicated for adjuvant radiation therapy and neo‐adjuvant/adjuvant chemotherapy. Results Of 142,636 breast cancer patients, 870 (0.61%) were MBC patients. At diagnosis, the mean age of MBC patients was 10?years older than FBC patients (70 vs 60?years; P??.001). Advanced‐stage cancer was more frequently observed in MBC than in FBC (stage III/IV 18.9%/6.1% vs 10.6%/5.2%). Despite this, MBC patients were less likely to receive adjuvant radiation therapy and neo‐adjuvant/adjuvant chemotherapy. Gender was an independent treatment determinant factor for chemotherapy decisions. Conclusion MBC patients were older and had higher stages of cancer than FBC patients at diagnosis, but received suboptimal treatment.
机译:背景技术雄性乳腺癌(MBC)的发病率虽然罕见,但已经增加了增加。然而,MBC的目前的流行病学和实践模式仍然不清楚。该研究评估了日本女性乳腺癌(FBC)与MBC的特征和护理模式。方法采用国家医院癌症注册表(HBCR)数据库与诊断程序组合数据相关联,我们在2012年1月至2015年1月至2015年12月之间分析了新诊断的乳腺癌病例,在大型保健品质监测项目中参加了医院。我们使用逻辑回归模型来评估MBC和FBC之间的癌症治疗差异,所述患者被指示辅助放射治疗和新辅助/佐剂化疗。结果142,636例乳腺癌患者,870(0.61%)是MBC患者。在诊断时,MBC患者的平均年龄比FBC患者年龄为10岁(70 vs 60?岁; P?<001)。在MBC中比在FBC中更频繁地观察到晚期癌症(第III阶段/ IV 18.9%/ 6.1%Vs 10.6%/ 5.2%)。尽管如此,MBC患者不太可能接受佐剂放射治疗和新辅助/佐剂化疗。性别是化疗决策的独立治疗决定因素。结论MBC患者年龄较大,癌症阶段高于FBC患者,但受到次优处的治疗。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号